Search

Your search keyword '"Mhawech-Fauceglia, Paulette"' showing total 175 results

Search Constraints

Start Over You searched for: Author "Mhawech-Fauceglia, Paulette" Remove constraint Author: "Mhawech-Fauceglia, Paulette" Database Unpaywall Remove constraint Database: Unpaywall
175 results on '"Mhawech-Fauceglia, Paulette"'

Search Results

4. The association of histopathologic features after neoadjuvant chemo-immunotherapy with clinical outcome: Sub-analyses from the randomized double-blinded, placebo-controlled, Phase III IMagyn050/GOG3015/ENGOT-ov39 study

6. Two staged phase II clinical trial of Eribulin monotherapy in advanced or recurrent cervical cancer

7. Factors Associated With Survival Disparities Between Non-Hispanic Black and White Patients With Uterine Cancer

8. Data from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

9. Supplementary Table 2 from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

10. Supplementary Figure Legends from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

11. Supplementary Figure 2 from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

12. Supplementary Figure 1 from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

13. Data from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

14. Supplementary Table 1 from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

15. Supplementary Table 1 from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

16. Supplementary Figure Legends from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

17. Supplementary Figure 2 from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

18. Supplementary Figure 1 from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

19. Supplementary Table 2 from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

22. Supplementary Data from Coordinated Cancer Germline Antigen Promoter and Global DNA Hypomethylation in Ovarian Cancer: Association with the BORIS/CTCF Expression Ratio and Advanced Stage

25. Data from Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer

26. Supplementary Figure 5 from Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer

27. Data from Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer

28. Supplementary Figure 1 from Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer

29. Supplementary Table 1 from Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer

30. Supplementary Figure 4 from Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer

31. Supplementary Figure 2 from Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer

32. Supplementary Figure 3 from Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer

33. Supplementary Materials, Legends for Figures 1-5 from Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer

34. Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues

38. P9 Mixed endometrial cancer a rare histology with the largest racial disparity in survival

39. Proteomic Alterations Associated with Residual Disease in Neoadjuvant Chemotherapy Treated Ovarian Cancer Tissues

44. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

45. Epigenetic Dysregulation of Trophoblastic Gene Expression in Gestational Trophoblastic Disease

46. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer

47. Phase II trial of eribulin in advanced/recurrent cervical cancer

48. Intersection of DNA Repair Pathways and the Immune Landscape Identifies PD-L2 as a Prognostic Marker in Epithelial Ovarian Cancer

Catalog

Books, media, physical & digital resources